ARTV
$6.32
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Intraday
Recent News
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update
Artiva Biotherapeutics (NASDAQ:ARTV) used a presentation and fireside chat at TD Cowen’s 46th Annual Healthcare Conference to outline its strategy in “deep B-cell depletion” for autoimmune disease, emphasizing rheumatoid arthritis (RA) as its lead indication and positioning its natural killer (NK) c
AtaiBeckley names Michael Faerm as finance chief
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25...
Undervalued Penny Stocks To Consider In January 2026
As the U.S. stock market begins a busy week of tech earnings and interest rate decisions, major indexes have seen gains following two weeks of losses, with gold reaching new heights amid geopolitical tensions. In this context, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for investors willing to explore beyond the mainstream. Despite their vintage name, these stocks can provide significant potential for growth when backed by strong...
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO’s Latest Insider Share Sale
Interest in Artiva Biotherapeutics (ARTV) has picked up after CEO Fred Aslan sold 3,187 shares on December 15, continuing a year long pattern of insider selling without any offsetting insider buys. See our latest analysis for Artiva Biotherapeutics. The insider activity lands at a time when sentiment around Artiva is clearly shifting. The latest $4.65 close caps a punchy 7 day share price return of 48.09 percent and a 90 day share price return of 61.46 percent, even though the year to date...
Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders
As the year draws to a close, U.S. markets are experiencing volatility, with major indexes closing lower amid concerns about an AI bubble and looming economic reports. In such a climate, investors often look beyond the large-cap stocks dominating headlines to explore opportunities in lesser-known areas like penny stocks. While the term "penny stocks" may seem outdated, it continues to signify smaller or emerging companies that could offer significant value when backed by strong financials and...